KCNN4 and asthma: In summary, this study has shown that the prolonged inhibition of the KCa3.1 channel by oral Senicapoc administration is effective at reducing the severity of allergen-induced early-phase bronchoconstriction, resting lung resistance, AHR, BAL eosinophilia and vascular remodelling in this sheep model of experimental asthma.